Several anti-HER2 agents, including trastuzumab, pertuzumab, lapatinib, neratinib, trastuzumab emtansine (T-DM1), and trastuzumab deruxtecan have been approved for the treatment of HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.